Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02246621 · OUTCOME

PK: Hepatic Clearance of Abemaciclib, and Apparent Hepatic Clearance of Its Metabolites M2 and M20

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer · Source last updated 2026-02-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
GEOMETRIC_MEAN
Unit
liters/hour (L/h)
Interval / dispersion
Geometric Coefficient of Variation
Time frame
Cycle 1 Day 1; 2 to 4 hours (h) post dose, Cycle 2 Day 1; 3 h post dose; 7 h post dose, Cycle 3 Day 1; pre dose, 3 h post dose

What was measured

PK: Hepatic Clearance of Abemaciclib, and apparent hepatic clearance of its Metabolites M2 and M20

Analysis population: All randomized participants who received at least one dose of study drug with evaluable PK data.

Groups in this outcome

Abemaciclib + NSAI

150 mg Abemaciclib orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Abemaciclib + NSAI322

Reported measurements

Abemaciclib
Values in liters/hour (L/h) · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Abemaciclib + NSAI23.026.7Not reportedNot reportedNot reported
M2
Values in liters/hour (L/h) · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Abemaciclib + NSAI21.650.4Not reportedNot reportedNot reported
M20
Values in liters/hour (L/h) · Interval/dispersion: Geometric Coefficient of Variation
GroupValueSpreadLowerUpperComment
Abemaciclib + NSAI26.046.4Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        26.7
        value
        23.0
    title
    Abemaciclib
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        50.4
        value
        21.6
    title
    M2
  3. categories
    1. measurements
      1. group Id
        OG000
        spread
        46.4
        value
        26.0
    title
    M20
denoms
  1. counts
    1. group Id
      OG000
      value
      322
    units
    Participants
description
PK: Hepatic Clearance of Abemaciclib, and apparent hepatic clearance of its Metabolites M2 and M20
dispersion Type
Geometric Coefficient of Variation
groups
  1. description
    150 mg Abemaciclib orally every 12 hours plus either 1 mg anastrozole or 2.5 mg letrozole orally once daily for 28 days (28 day cycles).
    id
    OG000
    title
    Abemaciclib + NSAI
param Type
GEOMETRIC_MEAN
population Description
All randomized participants who received at least one dose of study drug with evaluable PK data.
reporting Status
POSTED
time Frame
Cycle 1 Day 1; 2 to 4 hours (h) post dose, Cycle 2 Day 1; 3 h post dose; 7 h post dose, Cycle 3 Day 1; pre dose, 3 h post dose
title
PK: Hepatic Clearance of Abemaciclib, and Apparent Hepatic Clearance of Its Metabolites M2 and M20
type
SECONDARY
unit Of Measure
liters/hour (L/h)

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice